Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Nebraska Cancer Specialists
mi
from
Omaha, NE
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Nebraska Cancer Specialists
mi
from
Omaha, NE
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
New York Oncology Hematology
mi
from
New York, NY
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
New York Oncology Hematology
mi
from
New York, NY
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Waverly Hematology Oncology
mi
from
Cary, NC
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Waverly Hematology Oncology
mi
from
Cary, NC
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Duke University
mi
from
Durham, NC
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Texas Oncology - Baylor
mi
from
Dallas, TX
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Texas Oncology - Baylor
mi
from
Dallas, TX
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Texas Oncology
mi
from
Houston, TX
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Texas Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
The Mayo Clinic
mi
from
Rochester, MN
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Mt. Sinai Hosp., Marvette Koffler Breast Center
mi
from
Toronto,
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Mt. Sinai Hosp., Marvette Koffler Breast Center
mi
from
Toronto,
Click here to add this to my saved trials
PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening
Promoting Informed Decisions About Lung Cancer Screening: Randomized Trial
Status: Enrolling
Updated:  3/7/2017
Information and Quality Healthcare (IQH)
mi
from
Ridgeland, MS
PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening
Promoting Informed Decisions About Lung Cancer Screening: Randomized Trial
Status: Enrolling
Updated: 3/7/2017
Information and Quality Healthcare (IQH)
mi
from
Ridgeland, MS
Click here to add this to my saved trials
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Phase I Study of Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Status: Enrolling
Updated:  3/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Phase I Study of Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Status: Enrolling
Updated: 3/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated:  3/9/2017
DCSNO Carrollton Medical Center
mi
from
New Orleans, LA
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated: 3/9/2017
DCSNO Carrollton Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated:  3/9/2017
DCSNO St Cecelia Medical Center
mi
from
New Orleans, LA
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated: 3/9/2017
DCSNO St Cecelia Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated:  3/9/2017
EXCELth - Ida Hymel Community Health Center
mi
from
New Orleans, LA
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated: 3/9/2017
EXCELth - Ida Hymel Community Health Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated:  3/9/2017
Tulane Communty Health Center at Covenant House
mi
from
New Orleans, LA
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated: 3/9/2017
Tulane Communty Health Center at Covenant House
mi
from
New Orleans, LA
Click here to add this to my saved trials
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated:  3/9/2017
Tulane Faculty Practice
mi
from
New Orleans, LA
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
Status: Enrolling
Updated: 3/9/2017
Tulane Faculty Practice
mi
from
New Orleans, LA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Tucson, AZ
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Atherton, CA
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Atherton, CA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
La Mesa, CA
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
La Mesa, CA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Long Beach, CA
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
San Diego, CA
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Denver, CO
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Englewood, CO
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
New Britain, CT
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
New Britain, CT
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Aventura, FL
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Aventura, FL
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Naples, FL
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Jeffersonville, IN
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Shreveport, LA
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Annapolis, MD
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Annapolis, MD
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Baltimore, MD
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Brick, NJ
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Brick, NJ
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Albuquerque, NM
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Garden City, NY
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Garden City, NY
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
New York, NY
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Germantown, TN
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Carrollton, TX
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/9/2017
University of Colorado
mi
from
Aurora, CO
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/9/2017
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/9/2017
Roswell Park Cancer Center, Elm & Carlton Streets
mi
from
Buffalo, NY
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/9/2017
Roswell Park Cancer Center, Elm & Carlton Streets
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/9/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/9/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Foundation for Cancer Research and Education
mi
from
Phoenix, AZ
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Foundation for Cancer Research and Education
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Tucson
mi
from
Tucson, AZ
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials